期刊文献+

利用高分辨率熔解曲线分析法检测结直肠癌中KRAS基因突变 被引量:11

Detecting KRAS mutations in colorectal carcinoma patients with high resolution melting curve analysis
原文传递
导出
摘要 目的探讨利用新的高分辨率熔解曲线分析法检测结直肠癌中KRAS基因突变的可行性。方法首先采用直接测序法检测15例III期结直肠癌患者中KRAS基因第2外显子上第12和13号密码子的突变情况,继而以高分辨率熔解曲线分析法对直接测序的结果进行验证。结果经直接测序,确认15例结直肠癌患者中有6例发生了KRAS基因突变(40%),突变患者的基因型为:GGT>GAT型占2例,GGT>GTT占2例,GGC>GAC型占1例,GGC>GAA占1例。通过高分辨率熔解曲线分析法对以上15例标本进行进一步验证,证实所有患者的突变情况㈦直接测序方法的结果完全吻合。结论新的高分辨率熔解曲线分析法在检测KRAS基因突变时比直接测序法具有耗时短,易操作的优点,并且检测成本低廉,适合在临床开展。 Objective To evaluate the feasibility and sensitivity of detecting the mutations of KRAS in colorectal carcinoma patients with high resolution mehing curve analysis. Methods Direct sequencing was applied to detect the mutations of KRAS eodon 12 and 13 of 15 patients with stage III eolorectal carcinoma. Then the results were confirmed with high resolution melting curve analysis. Results By direct sequencing, 6 of 15 patients (40%) were found to carry KRAS mutations, and the distributions were 2 patients harboring GGT〉GAT mutation, 2 patients harboring GGT〉GTF mutation, 1 patient harboring GGC〉GAC mutation and 1 patient harboring GGC〉GAA mutation. By high resolution melting curve analysis, consistent results of the patients with mutations or without mutations were got. Conclusions The new high resolution melting curve analysis is more efficient, more convenient than direct sequencing. Moreover, it is a low-cost test, which is suitable for clinic test.
出处 《中华普通外科学文献(电子版)》 2009年第5期14-16,共3页 Chinese Archives of General Surgery(Electronic Edition)
基金 中山大学医科青年教师科研启动基金项目(2008005)
关键词 结直肠癌 突变 KRAS基因 高分辨率熔解曲线分析 Colorectal neoplasms Mutation KRAS gene High resolution melting curve analysis
  • 相关文献

参考文献8

  • 1Cunningham D,Humblet Y,Siena S,et al.Cetuximab monotherapy and cetuximab plus irinotecan in irinotecan-refractory metastatic colorectal cancer[].New England Journal of Homeopathy.2004
  • 2Saltz LB,Meropol NJ,Loehrer PJ Sr,et al.Phase II trial of cetuximab in patients with refractory colorectal cancer that expresses the epidermal growth factor receptor[].Journal of Clinical Oncology.2004
  • 3Karapetis CS,Khambata-Ford S,Jonker DJ,O‘Callaghan CJ,Tu D,Tebbutt NC,Simes RJ,Chalchal H,Shapiro JD,Robitaille S,Price TJ,Shepherd L,Au HJ,Langer C,Moore MJ,Zalcberg JR.K-ras mutations and benef it from cetuximab in advanced colorectal cancer[].The New England Journal of Medicine.2008
  • 4E Cutsem,M Peeters,S Siena.Open-label phase III trial of panitumumab plus best supportive care compared with best supportive care alone in patients with chemotherapy-refractory metastatic colorectal cancer[].Journal of Clinical Oncology.2007
  • 5Schrag,D.The price tag on progress--chemotherapy for colorectal cancer[].The New England Journal of Medicine.2004
  • 6C. Bokemeyer,I. Bondarenko,A. Makhson, et al.Fluorouracil, Leucovorin, and Oxaliplatin With and Without Cetuximab in the First-Line Treatment of Metastatic Colorectal Cancer[].Journal of Clinical Oncology.2009
  • 7Do H,Krypuy M,Mitchell PL,et al.High resolutionmelting analysis for rapid and sensitive EGFR andKRAS mutation detection in formalin fixed paraffinembedded biopsies[].BMC Cancer.2008
  • 8Krypuy,M,Newnham,GM,Thomas,DM,Conron,M,Dobrovic,A.High resolution melting analysis for the rapid and sensitive detection of mutations in clinical samples: KRAS codon 12 and 13 mutations in non-small cell lung cancer[].BMC Cancer.2006

同被引文献132

引证文献11

二级引证文献50

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部